# US 2012/0252871 A1 · Diagnosis and treatment of chronic lymphocytic leukemia (cll)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252871 A1
- Document ID: US20120252871A1
- Status: Published application
- Kind: A1
- Application number: 13/423,129
- Filed: 2012-03-16
- Published: 2012-10-04
- Earliest claimed: 2011-03-18
- Assignees: Institute for Systems Biology
- Inventors: David GALAS; Kai WANG; Guy BERCHEM; Etienne MOUSSAY
- Web page: https://patentgrep.com/patent/US20120252871A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/02: specific for leukemia
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

New markers in the form of miRNA levels in plasma are provided for indicating the presence of CLL in a subject as well as suggesting routes of therapeutic treatment.

## Claims

### Claim 1

A method to screen subjects for a positive indicator of chronic lymphocytic leukemia (CLL) which method comprises assessing plasma of at least one test subject for total miRNA level and comparing said miRNA level to that of one or more normal subjects, whereby a statistically significant increase in level of total miRNA in said test subject is an indicator that said subject may have CLL.

### Claim 2

A method to assess aggressiveness of CLL in a subject, which method comprises assessing the plasma of said subject for miR-20a and/or miR-16 whereby a lower level of said miR-20a and/or miR-16 in said subject as compared to normal subjects indicates the CLL of said subjects is aggressive.

### Claim 3

A method to evaluate a subject for the presence of CLL which method comprises
(a) determining the levels of miR-202 and/or miR-708 and/or miR-363 and/or miR-769-5p and/or miR-34a and/or miR-564 and/or miR-34a* and/or miR-27a* and/or miR-584 to determine a spectrum of levels comprising at least three of said miRNA species and comparing said spectrum to the spectrum of said at least three miRNAs in normal subjects whereby a spectrum having the characteristics set forth for said miRNAs in FIGS. 7A and 7B indicates the presence of CLL in said subject;
(b) assessing the plasma of said subject for the levels of miR-29a and/or miR-150 and/or miR-195 and/or miR-222, wherein statistically significant elevated assessed levels of said miRNAs as compared to normal subjects indicates the presence of CLL in the subject.

### Claim 4

(canceled)

### Claim 5

A method to treat CLL in a subject which method comprises effecting a diminution of expression of NR6A1 in said subject.

### Claim 6

(canceled)

### Claim 7

A method to monitor the progress of CLL in a subject which method comprises determining the level of miR-30e and/or miR-363 in the plasma of said subject over time, whereby if the level of said miR-30e decreases over time and/or the level of miR-363 increases over time, the CLL is indicated as progressing in said subject.

### Claim 8 (depends on 5)

The method of claim 5 wherein said diminution is effected by administering a composition that modulates the level of miR-23 and/or miR-181a in said subject.
